An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors

This study is testing a new experimental drug, XL309, to see if it is safe and effective at fighting advanced solid tumors. Researchers want to see if using this drug alone or combined with another medicine, olaparib, can help stop or slow down cancer growth.

This study is for adults 18 or older who have advanced cancer that hasn't responded to standard treatments. You must be well enough to carry out daily activities, and your vital organs must be functioning properly.

You will receive the study medication and be closely monitored by a medical team to ensure your safety and track how your body responds to the treatment. This helps researchers understand the drug's effects and determine the best way to use it.

The study is currently recruiting patients at locations in Fountain Valley, California, and Jacksonville and Orlando, Florida. You should speak with your doctor to see if one of these centers is a good fit for you.